SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23) [0.03%]
糖尿病治疗的SGLT2抑制剂专利回顾（2019-2023）
Rahul Baghel,Nikita Chhikara,Pawan Kumar et al.
Rahul Baghel et al.
Introduction: The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent anti-hypergly...
Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date [0.03%]
帕金森病发病机制中LRRK2抑制剂的研究进展及专利分析
Margaux Morez,Antonio Jesús Lara Ordóñez,Patricia Melnyk et al.
Margaux Morez et al.
Introduction: Nearly two decades after leucine rich repeat kinase 2 (LRRK2) was discovered as a genetic determinant of Parkinson's disease (PD), LRRK2 has emerged a priority therapeutic target in PD and inhibition of its ...
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present [0.03%]
2020年以来小分子CDK4/6抑制剂的专利分析及在抗肿瘤治疗中的应用综述
Xiaoling Huang,Shidi Xu,Lei Duan et al.
Xiaoling Huang et al.
Introduction: Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as breast can...
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present) [0.03%]
Polo样蛋白激酶(PLK)抑制剂的研发进展(2018-至今)专利回顾
Shirong Bian,Ru Zhang,Jianyu Nie et al.
Shirong Bian et al.
Introduction: Polo-like kinases (PLKs) have five isoforms, all of which play crucial roles in cell cycle and cell proliferation, offering opportunities for drug design and treatment of cancers and other related diseases. ...
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present) [0.03%]
磷二酯酶9(PDE9)抑制剂的治疗潜力（2018-今）——专利回顾
Chen Zhang,Zhao-Hang Xue,Wei-Hao Luo et al.
Chen Zhang et al.
Introduction: Phosphodiesterase 9 (PDE9) has been demonstrated as a potential target for neurological disorders and cardiovascular diseases, such as Alzheimer's disease and heart failure. For the last few years, a series ...
Therapeutic potential of boswellic acids: an update patent review (2016-2023) [0.03%]
乳香酸类化合物的治疗潜力：2016-2023年专利回顾更新
Hidayat Hussain,Daijie Wang,Hesham R El-Seedi et al.
Hidayat Hussain et al.
Introduction: Boswellic acids (BAs) are a group of pentacyclic triterpenoids of the ursane and oleanane type. They have shown very interesting biological properties that have led to the development of a number of synthesi...
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023) [0.03%]
选择性COX-2抑制剂作为抗癌药物的专利回顾（2018-2023）
Mohammad Mahboubi-Rabbani,Amir Hossein Abdolghaffari,Mahsa Ghesmati et al.
Mohammad Mahboubi-Rabbani et al.
Introduction: COX-2 is a crucial enzyme in the manufacture of prostaglandins. The enzyme's metabolites might have an important function as regulators of the inflammatory response and other medical conditions such as cance...
Ya-Xi Ye,Yu-Yao Cao,Li-Sheng Xu et al.
Ya-Xi Ye et al.
Introduction: Focal adhesion kinase (FAK) is a cytoplasmic non-receptor tyrosine kinase over-expressed in various malignancies which is related to various cellular functions such as adhesion, metastasis and proliferation....
Protein tyrosine phosphatase inhibitors: a patent review and update (2012-2023) [0.03%]
蛋白质酪氨酸磷酸酶抑制剂专利综述与更新（2012-2023）
Lakshmi Mounika Kelam,Vaishnavi Chhabra,Sarika Dhiman et al.
Lakshmi Mounika Kelam et al.
Introduction: Protein tyrosine phosphatases (PTPs), essential and evolutionarily highly conserved enzymes, govern cellular functions by modulating tyrosine phosphorylation, a pivotal post-translational modification for si...
An updated patent review on PD-1/PD-L1 antagonists (2022-present) [0.03%]
2022年以来PD-1/PD-L1抑制剂专利梳理及展望
Wiktor Uzar,Beata Kaminska,Hubert Rybka et al.
Wiktor Uzar et al.
Introduction: PD-L1, via its interactions with PD-1, constitutes a key immune checkpoint that allows cancer cells to escape immune surveillance. Targeting PD-1/PD-L1 with monoclonal antibodies (mAbs) led to spectacular su...